Katie Suda, Pharm.D., professor of medicine at the University of Pittsburgh Center for Research on Health Care, and Malavika Tampi, manager of the ADA Center for Evidence-Based Dentistry, will join other leaders in Clostridium difficile prevention and treatment, antimicrobial resistance and stewardship, health care policy, state and federal government, and grassroots organizing in discussing the C. diff public health threat and training advocates to combat it during the National C. diff Advocacy Summit.
The April 20-22 summit will convene from noon-4 p.m. EDT each day. This year's event is online because of the COVID-19 pandemic.
In addition to the presentation on C. diff infections and antibiotic stewardship in dentistry, other sessions will discuss the quality of life for patients with C. diff infections in the U.S., the impact of COVID-19 on C. diff clinical trials and more.
The ADA's guideline advises against using antibiotics to manage most dental pain and intraoral swelling associated with pulpal and periapical infections and instead recommends only the use of dental treatment and, if needed, over-the-counter pain relievers, such as acetaminophen or ibuprofen. The guideline helped the ADA fulfill its pledged commitment to the Antimicrobial Resistance Challenge, an initiative organized by the U.S. government to combat antimicrobial resistance.
To learn more or register for the conference, visit the Peggy Lillis Foundation website. The foundation is the leading organization combating C. diff infections and antibiotic resistance through education and advocacy.